CARDIOPROTECTIVE PHARMACEUTICAL TREATING ANTHRACYCLINE

Brand Owner (click to sort) Address Description
ANTHRAGARD ERBAMONT INC. P.O. BOX 16529 COLUMBUS OH 432166529 CARDIOPROTECTIVE PHARMACEUTICAL FOR TREATING ANTHRACYCLINE INDUCED CARDIOTOXICITY;
ZINECARD ERBAMONT INC. P.O. BOX 16529 COLUMBUS OH 432166529 CARDIOPROTECTIVE PHARMACEUTICAL FOR TREATING ANTHRACYCLINE INDUCED CARDIOTOXICITY;
ZINECARD PHARMACIA & UPJOHN COMPANY 7000 Portage Road Kalamazoo MI 49001 cardioprotective pharmaceutical for treating anthracycline induced cardiotoxicity;
ZINECOR ERBAMONT INC. P.O. BOX 16529 COLUMBUS OH 432166529 CARDIOPROTECTIVE PHARMACEUTICAL FOR TREATING ANTHRACYCLINE INDUCED CARDIOTOXICITY;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The present invention relates to a method for treating cancer using p38/JTV-1 and a method for screening pharmaceutical composition for treating cancer. More particularly, this invention relates to the method for treating cancer, which comprises administering the effective amount of p38/JTV-1 protein or a nucleic acid encoding for said protein to the patient and the method for screening a pharmaceutical composition for treating cancer characterized by selecting a substance having an effect on the increase of the activity of the p38/JTV-1 protein and the intracellular level thereof.